I]IUdR, supporting a sustained release profile. DNA incorporation assays and viability studies in glioblastoma cells confirmed the biological activity and radiotoxicity of the released compound. This work highlights the potential of PeptoBrushes for controlled radionuclide delivery of Auger-emitting radiotherapeutic agents, laying the foundation for an innovative strategy in glioblastoma therapy.
Schäfer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: